Epigenetics (Apr 2018)
Epigenetics of gastrointestinal diseases: notes from a workshop
- David L. Marks,
- Rachel L. Olson,
- Raul Urrutia,
- Daniel D. Billadeau,
- Nilotpal Roy,
- George A. Calin,
- Muller Fabbri,
- Marina Koutsioumpa,
- Dimitrios Iliopoulos,
- Tamas Ordog,
- Robert Huebert,
- Olga Sarmento,
- Adebowale O. Bamidele,
- William Faubion,
- Gwen L. Lomberk,
- Jens Siveke,
- Nita Ahuja,
- Juan Iovanna,
- Ryan A. Hlady,
- Keith Robertson,
- John Kisiel,
- Christopher L. Pin,
- Martin E. Fernandez-Zapico
Affiliations
- David L. Marks
- Mayo Clinic
- Rachel L. Olson
- Mayo Clinic
- Raul Urrutia
- Medical College of Wisconsin
- Daniel D. Billadeau
- Mayo Clinic
- Nilotpal Roy
- University of California at San Francisco
- George A. Calin
- MD Anderson Cancer Center
- Muller Fabbri
- University of Southern California
- Marina Koutsioumpa
- University of California at Los Angeles
- Dimitrios Iliopoulos
- University of California at Los Angeles
- Tamas Ordog
- Mayo Clinic
- Robert Huebert
- Mayo Clinic
- Olga Sarmento
- Mayo Clinic
- Adebowale O. Bamidele
- Mayo Clinic
- William Faubion
- Mayo Clinic
- Gwen L. Lomberk
- Medical College of Wisconsin
- Jens Siveke
- University Hospital Essen
- Nita Ahuja
- Yale School of Medicine
- Juan Iovanna
- Institut Paoli-Calmettes
- Ryan A. Hlady
- Mayo Clinic
- Keith Robertson
- Mayo Clinic
- John Kisiel
- Mayo Clinic
- Christopher L. Pin
- The University of Western Ontario
- Martin E. Fernandez-Zapico
- Mayo Clinic
- DOI
- https://doi.org/10.1080/15592294.2018.1464351
- Journal volume & issue
-
Vol. 13,
no. 4
pp. 449 – 457
Abstract
International experts gathered at the Mayo Clinic (Rochester MN, USA) on February 27th-28th, 2017 for a meeting entitled ‘Basic and Translational Facets of the Epigenetics of GI Diseases’. This workshop summarized recent advances on the role of epigenetics in the pathobiology of gastrointestinal (GI) diseases. Highlights of the meeting included recent advances on the involvement of different epigenetic mechanisms in malignant and nonmalignant GI disorders and the epigenetic heterogeneity exhibited in these diseases. The translational value of epigenetic drugs, as well as the current and future use of epigenetic changes (i.e., DNA methylation patterns) as biomarkers for early detection tools or disease stratification were also important topics of discussion.
Keywords
